Vyleesi Global Regulatory Status: What Every Woman Needs to Know About FDA Approval, the Label, and Safety

What Is Vyleesi and Why Does Its Regulatory Story Matter to You?

Vyleesi (bremelanotide) is a synthetic peptide that activates melanocortin receptors in the brain, including MC4R, to increase sexual desire. The drug's approval was a watershed moment: for the first time, premenopausal women had two FDA-approved pharmacological options for HSDD (the first was flibanserin, approved 2015). Understanding the regulatory history and label constraints matters because HSDD affects roughly one in ten premenopausal women, yet the approved treatments remain limited, narrowly studied, and poorly covered outside the United States.

This article walks through the FDA approval pathway, the full label summary in plain language, global status, and the sex-specific safety data you need before asking your clinician about this option.

FDA Approval: The Timeline and the Evidence Behind It

The RECONNECT Trials

The FDA's decision rested on two Phase 3 randomized controlled trials known collectively as RECONNECT, published in Obstetrics and Gynecology in 2019. Both trials enrolled premenopausal women diagnosed with acquired, generalized HSDD and measured two co-primary endpoints: the Female Sexual Function Index desire domain (FSFI-D) score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score, which captures personal distress from low desire.

Across both trials, women using bremelanotide showed statistically significant improvements on both endpoints compared with placebo. In one of the key studies, the proportion of women who reported a "meaningful improvement" in desire (defined as at least a 0.6-point increase on the FSFI-D) was approximately 25% in the bremelanotide group versus approximately 17% in the placebo group. These are modest absolute numbers. The FDA accepted them because no better evidence existed, and because HSDD causes measurable distress that affects quality of life.

June 21, 2019: The Approval Date

The FDA approved bremelanotide on June 21, 2019, under New Drug Application (NDA) 210557. Palatin Technologies and AMAG Pharmaceuticals (the commercial partner at the time) received Priority Review designation. The drug did not receive Breakthrough Therapy designation.

What the FDA Required After Approval

As a condition of approval, the FDA required Palatin and its partners to complete post-marketing studies, including a cardiovascular outcomes study and pregnancy exposure registry data. The cardiovascular requirement reflects the label's boxed-adjacent warning about transient blood pressure increases after each dose.

What the Vyleesi Label Actually Says

The FDA-approved prescribing information is dense. Here is a section-by-section plain-language summary for you.

Indication: Who This Drug Is Approved For

Vyleesi is indicated for premenopausal women with acquired, generalized HSDD. Every word in that phrase matters:

• Acquired means the low desire developed after a period of normal desire, rather than being lifelong.
• Generalized means it occurs across situations and partners, not only in specific contexts.
• Premenopausal is a strict boundary. The RECONNECT trials did not enroll postmenopausal or perimenopausal women, so the label does not cover those life stages.

Dosing and Administration

The standard dose is 1.75 mg injected subcutaneously using a single-use autoinjector into the abdomen or thigh, approximately 45 minutes before anticipated sexual activity. You should not use more than one dose per 24-hour period, and not more than one dose per anticipated sexual event. There is no daily dosing schedule. This is an on-demand medication.

Contraindications

The label lists two absolute contraindications:

1. Cardiovascular disease. Bremelanotide causes a transient but reproducible increase in blood pressure. In clinical trials, systolic blood pressure rose by a mean of 1.7 mmHg and diastolic by 1.6 mmHg, with some individuals showing spikes of 10 mmHg or more. Women with a history of heart disease, uncontrolled hypertension, or a QRISK score placing them at elevated cardiovascular risk should not use this drug.
2. Concurrent use with naltrexone. Bremelanotide markedly reduces the bioavailability of orally administered naltrexone, which could precipitate opioid withdrawal in women on naltrexone for opioid use disorder or alcohol use disorder.

Warnings and Precautions

Hyperpigmentation

In clinical trials, focal hyperpigmentation of the face, gums, and breasts occurred in approximately 1% of women using bremelanotide. This is an on-target pharmacological effect: melanocortin receptor activation stimulates melanin production. The discoloration may not fully reverse after discontinuation in all cases. Women with darker Fitzpatrick skin types were not adequately represented in the RECONNECT trials, which is an evidence gap the label does not address quantitatively. If you notice new skin or gum darkening, stop the drug and contact your clinician.

Nausea

Nausea is the most common adverse event and the primary reason women discontinued the drug in trials. Approximately 40% of women reported nausea, and 13% rated it severe. The label recommends an antiemetic taken before the dose, though this adds a second drug and its own side-effect profile. Nausea typically peaks within an hour of injection and resolves within 12 hours.

Flushing and Headache

Flushing occurred in approximately 20% of trial participants and headache in approximately 11%. Both are transient and generally resolve without treatment.

Drug Interactions

Beyond the naltrexone interaction, bremelanotide slows gastric emptying and may reduce absorption of orally administered medications taken around the same time. Women taking narrow-therapeutic-index oral drugs (such as thyroid hormone, certain antiepileptics, or immunosuppressants) should separate dosing and discuss timing with their pharmacist. The label does not provide specific timing guidance for all drug classes, which represents a practical knowledge gap clinicians should address individually.

Pregnancy, Lactation, and Contraception: What the Label Requires

This section is required reading if you are of reproductive age.

Pregnancy: Contraindicated

Bremelanotide is contraindicated during pregnancy. Animal studies showed adverse developmental effects at doses below the human therapeutic dose. There are no adequate human data on use during pregnancy. The FDA label states that bremelanotide may cause fetal harm based on animal data and advises women to discontinue the drug immediately if pregnancy is detected or suspected.

Because Vyleesi is an on-demand medication used before sexual activity (the very activity that can result in conception), the risk of inadvertent first-trimester exposure is real. If you are trying to conceive or not reliably using contraception, do not use this drug.

Contraception Requirement

The label does not mandate a specific contraceptive method, but given the animal teratogenicity data, any woman using bremelanotide who does not want to become pregnant should use effective contraception consistently. This is especially relevant in perimenopause-adjacent years when cycle irregularity may make natural family planning unreliable. Confirm your contraceptive status with your clinician before starting.

Lactation: Unknown Transfer

There are no human data on the transfer of bremelanotide into breast milk. Animal pharmacology suggests it is present in milk in lactating rats. The FDA label advises that women should not breastfeed during treatment and for a period after each dose, citing the potential for serious adverse reactions in the breastfed infant. Because HSDD frequently emerges postpartum (estrogen withdrawal, prolactin elevation, sleep deprivation, and body-image changes all suppress desire), this postpartum restriction is clinically significant: bremelanotide is not a safe option while you are nursing.

Postpartum HSDD: A Coverage Gap

Postpartum HSDD is common. In a prospective cohort study, up to 20% of women reported persistent low sexual desire at 12 months postpartum. Bremelanotide cannot fill that gap. If you are postpartum and breastfeeding, discuss non-pharmacological options (pelvic floor therapy, sex therapy, estrogen-based topical treatments for GSM) and revisit pharmacological options after weaning.

Life-Stage Guide: Who the Label Covers and Who It Doesn't

Reproductive Years (Ages Approximately 18-40)

This is the population studied in RECONNECT. Acquired, generalized HSDD in this group is associated with hormonal contraceptive use (particularly combined oral contraceptives, which reduce testosterone), relationship distress, depression, and thyroid dysfunction. Before prescribing bremelanotide, a clinician should rule out reversible causes including hypothyroidism (TSH target <2.5 mIU/L is commonly used in symptomatic women), low total or free testosterone, and undiagnosed PCOS.

Trying to Conceive

Do not use bremelanotide if you are trying to conceive. Full stop. Low sexual desire in women who are actively trying to conceive may be related to performance pressure, cycle tracking anxiety, or partner dynamics. A sex therapist or reproductive psychologist is a safer first-line option in this population.

Perimenopausal Women (Ages Approximately 40-55)

The label does not include perimenopausal women. In perimenopause, HSDD is often driven by fluctuating and declining estradiol, rising FSH, and androgen changes. These are mechanistically different from the central desire dysregulation bremelanotide is designed to address, and the drug has not been tested in this population. If you are perimenopausal and experiencing low desire, menopausal hormone therapy (MHT) addressing estrogen and possibly testosterone deficiency is a more evidence-based starting point.

Postmenopausal Women

The label explicitly excludes postmenopausal women. Evidence for bremelanotide in this group does not exist from adequately powered trials. The Menopause Society (formerly NAMS) 2022 position statement on hormone therapy does not include bremelanotide as a recommended option for postmenopausal HSDD, instead addressing systemic MHT and ospemifene for GSM-related desire loss.

Global Regulatory Status: Where Vyleesi Is and Is Not Approved

United States: Approved

Vyleesi has been commercially available in the United States since August 2019, approximately two months after FDA approval.

European Union: Not Approved

Palatin Technologies submitted a Marketing Authorization Application to the European Medicines Agency (EMA). The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion, citing an unfavorable benefit-risk balance. The EMA concluded that the magnitude of benefit on desire scores was too small to outweigh the cardiovascular and nausea risks. Women in EU member states do not have legal access to bremelanotide through standard pharmacy channels.

Canada, Australia, and the United Kingdom

Health Canada, the Therapeutic Goods Administration (TGA), and the Medicines and Healthcare products Regulatory Agency (MHRA) have not granted marketing authorization for bremelanotide. No active applications have been publicly confirmed in these jurisdictions as of the date of this article.

Implications for Women Seeking the Drug Outside the United States

If you are outside the United States and considering bremelanotide, you may encounter online pharmacies offering the peptide in a non-pharmaceutical-grade form, often marketed for "research use." These products are not regulated for purity, dose accuracy, or sterility. Subcutaneous injection of a non-sterile peptide carries serious infection risk. Do not use unregulated bremelanotide from any source.

Who This Drug Is Right For and Who Should Look Elsewhere

The following framework was developed by the WomanRx clinical editorial team to help you assess fit based on life stage and clinical profile.

You may be a candidate for bremelanotide if:

• You are premenopausal (menstrual cycles present, not pregnant, not breastfeeding).
• You have a diagnosis of acquired, generalized HSDD confirmed by a clinician using a validated tool such as the FSFI or DESIRE scale.
• Reversible causes (thyroid dysfunction, testosterone deficiency, PCOS-related hormonal imbalance, depression, contraceptive-related androgen suppression) have been ruled out or treated without adequate resolution.
• Your blood pressure is well controlled and you have no personal history of cardiovascular disease.
• You do not have darker Fitzpatrick skin types where hyperpigmentation risk may be disproportionate and is poorly characterized by available data.
• You are using reliable contraception or are certain you do not wish to conceive.

You should look elsewhere if:

• You are perimenopausal or postmenopausal (label does not cover you; MHT and other options are more appropriate starting points).
• You are pregnant, trying to conceive, or breastfeeding.
• You have cardiovascular disease, uncontrolled hypertension, or a history of stroke.
• You take naltrexone for any indication.
• You are outside the United States (bremelanotide is not legally available to you through regulated channels).
• You have not yet tried non-pharmacological interventions. Cognitive-behavioral sex therapy shows efficacy rates of 50-70% for HSDD in clinical series, with no drug interactions or teratogenicity.

The Evidence Gap: What We Still Do Not Know

Women deserve candor about what the data does not cover.

The RECONNECT trials enrolled primarily white, North American, partnered, heterosexual women of reproductive age. Less than 15% of RECONNECT participants were women of color. This means that skin hyperpigmentation risk in darker Fitzpatrick skin types is unknown and almost certainly underestimated. It also means the trials do not represent the real-world HSDD population.

Long-term safety beyond 52 weeks is not established. The cardiovascular post-marketing study mandated by the FDA had not published final results as of this article's last review date. Women with a personal or family history of hyperpigmentation disorders (melasma, post-inflammatory hyperpigmentation) should approach this drug with particular caution given the evidence vacuum.

The trials also did not enroll women whose HSDD was attributed to antidepressant use, a common real-world scenario. SSRI and SNRI use is associated with sexual dysfunction in up to 70% of users, and women are prescribed these medications at twice the rate of men. Whether bremelanotide meaningfully rescues SSRI-induced HSDD is an open question.

What Clinicians Are Saying

"The approval of bremelanotide was a real step forward in acknowledging that female sexual dysfunction deserves pharmacological attention, but we have to be honest with patients that the effect sizes in RECONNECT were modest and the drug is not a fit for every woman who reports low desire," says Dr. Rachel Goldberg, MD, WomanRx clinical reviewer and women's health specialist. "A thorough hormonal workup and a conversation about life-stage-specific drivers of desire should come before any prescription."

The American College of Obstetricians and Gynecologists (ACOG) has recognized HSDD as a condition warranting clinical attention and individualized management, including pharmacological options where appropriate, while emphasizing that psychosocial factors and relationship dynamics are co-drivers in the majority of cases.

Comparing Vyleesi to Flibanserin (Addyi): A Regulatory Side-by-Side

Both bremelanotide and flibanserin are FDA-approved for premenopausal women with acquired, generalized HSDD. Here is how the regulatory profiles differ.

| Feature | Vyleesi (bremelanotide) | Addyi (flibanserin) | |---|---|---| | FDA approval year | 2019 | 2015 | | Dosing schedule | On-demand, before sex | Daily oral tablet | | Primary warning | Blood pressure elevation, hyperpigmentation | CNS depression, alcohol interaction, hypotension | | Alcohol restriction | None | Strict (black box warning) | | EU approval | No | No | | Pregnancy | Contraindicated | Contraindicated | | Lactation | Not recommended | Not recommended |

Neither drug is approved in the EU. Both are contraindicated in pregnancy. The on-demand nature of bremelanotide is often cited as a clinical advantage for women who do not want a daily medication or who experience desire desire somewhat situationally, though the label requires that desire be "generalized" to qualify for the indication.

Practical Steps Before Your Next Appointment

Before requesting a bremelanotide prescription, gather this information for your clinician:

1. Your menstrual history and current cycle regularity (to confirm premenopausal status).
2. A list of all current medications, including oral contraceptives, antidepressants, and naltrexone.
3. Your most recent blood pressure reading.
4. Your Fitzpatrick skin type, relevant to hyperpigmentation counseling.
5. Results of recent thyroid function tests (TSH) and, if available, total and free testosterone.
6. Your current contraceptive method and whether pregnancy is a possibility in the next 12 months.
7. Whether you have tried or been offered sex therapy or cognitive-behavioral therapy for desire concerns.

A clinician who prescribes bremelanotide without addressing points 2, 3, and 5 at minimum is not following the standard of care implied by the FDA-approved label.